Fredun Pharmaceuticals reveals a dramatic 90% increase in revenue and nearly 95% rise in net profit in its Q1 FY27 results, driven by strategic diversification into new healthcare sectors and expansion in global markets.
Fredun Pharmaceuticals said its unaudited first-quarter results for FY27 showed a sharp jump in performance, with total income rising 90.44% year on year to ₹228.25 crore, EBITDA increasing 92.90% to ₹32.78 crore and net profit climbing 94.63% to ₹13.17 crore. The Mumbai-based company, which sells generic medicines as well as cosmeceuticals, nutraceuticals, mobility products and animal health items, said the quarter reflected the growing impact of investments made across the business. LiveMint, meanwhile, tracked the quarter as one in which revenue and profit also rose on a yearly basis, though it used a different revenue base for the period.
Managing Director Fredun Medhora said the company is trying to build a broader healthcare business rather than depend on a single product line. In comments released with the results, he said the quarter validated the direction the company has taken in recent years and argued that Fredun is positioning itself for long-term growth through branded products, entry into new healthcare categories and stronger manufacturing capability. The company also said its EBITDA margin improved to 14.36%, while net profit margin reached 5.77%.
Arthneeti, in an analysis of the earnings, said Fredun is targeting 25% to 30% annual top-line growth over the coming years and has delivered a 32% compound annual growth rate over 19 years without a year of decline. The report said newer businesses such as pet care, mobility and nutraceuticals are growing at 40% to 50% from a smaller base, while the older pharmaceutical line is expanding at a steadier 10% to 15%. It added that the company expects margins to improve over the next 8 to 9 quarters as newer products scale up and distribution broadens.
Fredun also highlighted a recent bonus issue. On July 17, it allotted 1.10 crore bonus equity shares in a 2:1 ratio, lifting paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares. The company says it exports to Africa, south-east Asia, Commonwealth of Independent States countries and Latin America, and it reported full-year FY26 revenue of ₹639.12 crore, EBITDA of ₹94.79 crore and profit after tax of ₹33.21 crore.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
